BRPI0607016A2 - marcadores polipeptìdicos para o diagnóstico de cáncer de próstata - Google Patents

marcadores polipeptìdicos para o diagnóstico de cáncer de próstata

Info

Publication number
BRPI0607016A2
BRPI0607016A2 BRPI0607016-7A BRPI0607016A BRPI0607016A2 BR PI0607016 A2 BRPI0607016 A2 BR PI0607016A2 BR PI0607016 A BRPI0607016 A BR PI0607016A BR PI0607016 A2 BRPI0607016 A2 BR PI0607016A2
Authority
BR
Brazil
Prior art keywords
markers
diagnosis
prostate cancer
polypeptide
polypeptide markers
Prior art date
Application number
BRPI0607016-7A
Other languages
English (en)
Inventor
Harald Mischak
Original Assignee
Mosaiques Diagnostics & Therap
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mosaiques Diagnostics & Therap filed Critical Mosaiques Diagnostics & Therap
Publication of BRPI0607016A2 publication Critical patent/BRPI0607016A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)

Abstract

MARCADORES POLIPEPTìDICOS PARA O DIAGNóSTICO DE CáNCER DE PRóSTATA. Um método para o diagnóstico de câncer de próstata, compreendendo a etapa de determinar a presença ou ausência de no mínimo três marcadores polipeptídicos em uma amostra, em que o referido marcador polipeptídico é selecionado entre marcadores 1 a 44 e 52 a 78 (marcadores de freqúência), ou determinar a amplitude de no mínimo um marcador polipeptídico selecionado entre marcadores 45 a 51 e 79 a 115 (marcadores de amplitude), os quais são caracterizados pelos seguintes valores para as massas moleculares e tempos de migração:
BRPI0607016-7A 2005-04-07 2006-04-06 marcadores polipeptìdicos para o diagnóstico de cáncer de próstata BRPI0607016A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05102741 2005-04-07
EP05105434 2005-06-21
PCT/EP2006/061374 WO2006106129A2 (de) 2005-04-07 2006-04-06 Polypeptidmarker zur diagnose von prostatakrebs

Publications (1)

Publication Number Publication Date
BRPI0607016A2 true BRPI0607016A2 (pt) 2009-08-04

Family

ID=36609504

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607016-7A BRPI0607016A2 (pt) 2005-04-07 2006-04-06 marcadores polipeptìdicos para o diagnóstico de cáncer de próstata

Country Status (7)

Country Link
US (2) US20090298184A1 (pt)
EP (2) EP2317320A3 (pt)
JP (1) JP2008537112A (pt)
AU (1) AU2006231611B2 (pt)
BR (1) BRPI0607016A2 (pt)
CA (1) CA2604037A1 (pt)
WO (1) WO2006106129A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060286602A1 (en) * 2004-05-10 2006-12-21 Harald Mischak Method and markers for the diagnosis of renal diseases
EP2118666B1 (de) 2007-03-07 2011-08-03 Mosaiques Diagnostics And Therapeutics AG Verfahren zur normierung der konzentration von analyten in einer urinprobe
EP1972940A1 (de) * 2007-03-14 2008-09-24 mosaiques diagnostics and therapeutics AG Verfahren und Marker zur Diagnose von Nierenerkrankungen
EP2198305A2 (de) * 2007-10-09 2010-06-23 Mosaiques Diagnostics And Therapeutics AG Polypeptidmarker zur diagnose von prostatakrebs
EP2051078A1 (de) * 2007-10-19 2009-04-22 mosaiques diagnostics and therapeutics AG Verfahren und Marker zur Diagnose von Diabetes Mellitus
EP2255203A2 (de) * 2008-03-19 2010-12-01 Mosaiques Diagnostics And Therapeutics AG Verfahren und marker zur diagnose von tubulären nierenschäden und -erkrankungen
EP2338054A1 (de) * 2008-09-17 2011-06-29 Mosaiques Diagnostics And Therapeutics AG Nierenzellkarzinom
EP2487251A1 (de) * 2011-02-13 2012-08-15 Protagen AG Markersequenzen für die Diagnose von Prostatakarzinom und deren Verwendung
CN121208362A (zh) * 2025-11-25 2025-12-26 长兴固容生物科技有限公司 一种用于前列腺癌筛查、诊断的标志物组及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7868300A (en) * 1999-10-07 2001-05-10 Ciphergen Biosystems, Inc. Prostate cancer marker proteins
DE60127104D1 (de) * 2000-03-20 2007-04-19 Eastern Virginia Med School Prostatakrebs-marker
DE60120385T2 (de) 2000-03-30 2007-06-06 Orde Levinson Vorrichtung zum urinieren
DE10021737C2 (de) 2000-05-04 2002-10-17 Hermann Haller Verfahren und Vorrichtung zur qualitativen und/oder quantitativen Bestimmung eines Protein- und/oder Peptidmusters einer Flüssigkeitsprobe, die dem menschlichen oder tierischen Körper entnommen wird
US20030082654A1 (en) * 2001-08-03 2003-05-01 Parish Christopher Richard Novel cancer marker and uses therefor in the diagnosis of cancer
DE10142785C2 (de) 2001-08-31 2003-07-03 Henning Trappe Verfahren zur Bestimmung lokaler Ähnlichkeit aus seismischen 3D-Meßdaten
AU2003211157A1 (en) * 2002-02-21 2003-09-09 Eastern Virginia Medical School Protein biomarkers that distinguish prostate cancer from non-malignant cells
AU2003231084A1 (en) * 2002-04-26 2003-11-10 The Johns Hopkins University Identification of biomarkers for detecting prostate cancer
JP2005080524A (ja) * 2003-09-05 2005-03-31 Japan Science & Technology Agency 前立腺癌マーカポリペプチド、該ポリペプチドに対する抗体、及び該ポリペプチドを利用した前立腺癌の診断方法
DE10341193A1 (de) * 2003-09-06 2005-03-31 Mosaiques Diagnostics And Therapeutics Ag Vorrichtung und Verfahren zur quantitativen Auswertung der in einer Körperflüssigkeitsprobe enthaltenden Polypeptide sowie Marker zur Erkennung von pathologischen Zuständen

Also Published As

Publication number Publication date
AU2006231611A1 (en) 2006-10-12
US20150133343A1 (en) 2015-05-14
WO2006106129A3 (de) 2007-09-20
US20090298184A1 (en) 2009-12-03
EP2317320A3 (de) 2011-07-13
JP2008537112A (ja) 2008-09-11
WO2006106129A2 (de) 2006-10-12
CA2604037A1 (en) 2006-10-12
EP1866648A2 (de) 2007-12-19
AU2006231611B2 (en) 2012-12-06
EP2317320A2 (de) 2011-05-04

Similar Documents

Publication Publication Date Title
WO2009019368A3 (fr) Procede de dosage de la liver fatty acid-binding protein, de l'ace et du ca19-9 pour le diagnostic in vitro du cancer colorectal
BRPI0407397A (pt) Evento de algodão mon 88913 e composições e métodos para sua detecção
DE602006017365D1 (de) Zusammensetzungen für die identifizierung von adenoviren
EP1687283A4 (en) FOR THE DETERMINATION OF FK506 PROCEDURE AND COMPOSITION
EA200400816A1 (ru) Замещенные аналоги хиназолин-4-иламина в качестве модуляторов капсаицина
BR112012032537A2 (pt) biomarcadores de câncer de pulmão e suas utilizações
DE602005023529D1 (de) Homogener nachweis von analyten
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
CY1110337T1 (el) Παρασκευη πρεγκαμπαλινης και σχετικων ενωσεων
BRPI0418639A (pt) inibidores de dipeptidil peptidase
DE602004019812D1 (de) Marker für neuromyelitis optica
BRPI0417903A (pt) método de melhorar a detecção de sinal de um componente de parede celular de células
BRPI0413471A (pt) métodos para detectar um ou mais complexos de proteìnas e para detectar um complexo em uma amostra biológica
BR0115715A (pt) Análise de expressão de ácidos nucleìcos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
WO2009019365A3 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal
ATE492651T1 (de) Moesin, caveolin 1 und yes-assoziiertes protein 1 als prädiktive marker der reaktion auf dasatinib bei brustkrebs
AU2021269176A8 (en) Single domain antibodies binding to SARS-CoV-2 spike protein
BR0309153A (pt) Método para prognosticar uma pressão de formação à frente de uma broca em um poço, dispositivo de armazenamento de programa, e, sistema para prognosticar uma pressão de formação à frente de uma broca em um poço
BRPI0607016A2 (pt) marcadores polipeptìdicos para o diagnóstico de cáncer de próstata
DE602004031368D1 (de) Universelle vervielfältigung von fragmentierter rns
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
ATE487141T1 (de) Hemmung von gasc1
WO2006133923A3 (en) Diagnosis, prognosis and prediction of recurrence of breast cancer
BR0315178A (pt) Eritropoietina: remodelagem e glicoconjugação de eritropoietina
WO2009047280A3 (de) Polypeptidmarker zur diagnose von prostatakrebs

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]